BR112021017375A2 - Composição farmacêutica combinando método imunológico e quimioterapêutico para o tratamento de câncer - Google Patents

Composição farmacêutica combinando método imunológico e quimioterapêutico para o tratamento de câncer

Info

Publication number
BR112021017375A2
BR112021017375A2 BR112021017375A BR112021017375A BR112021017375A2 BR 112021017375 A2 BR112021017375 A2 BR 112021017375A2 BR 112021017375 A BR112021017375 A BR 112021017375A BR 112021017375 A BR112021017375 A BR 112021017375A BR 112021017375 A2 BR112021017375 A2 BR 112021017375A2
Authority
BR
Brazil
Prior art keywords
cancer
pharmaceutical composition
immunological
treatment
composition combining
Prior art date
Application number
BR112021017375A
Other languages
English (en)
Inventor
Rafferty Bostwick Brian
Granger Bostwick David
Original Assignee
Rampart Health L L C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rampart Health L L C filed Critical Rampart Health L L C
Publication of BR112021017375A2 publication Critical patent/BR112021017375A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A61B18/0218—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques with open-end cryogenic probe, e.g. for spraying fluid directly on tissue or via a tissue-contacting porous tip
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
    • A61B2018/00577—Ablation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A61B2018/0293—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques using an instrument interstitially inserted into the body, e.g. needle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

composição farmacêutica combinando método imunológico e quimioterapêutico para o tratamento de câncer. esta invenção refere-se a uma composição farmacêutica compreendendo pelo menos dois inibidores de ponto de controle imunológico, pelo menos um fármaco quimioterapêutico citotóxico ou citostático. esta invenção também se refere a um método de tratar um tumor ou um câncer em um paciente compreendendo administrar, a um paciente em necessidade do mesmo, a composição farmacêutica em quantidade eficaz para tratar o tumor ou câncer e, opcionalmente, uma etapa de ablação de pelo menos uma porção do tumor ou do câncer.
BR112021017375A 2019-03-01 2020-02-28 Composição farmacêutica combinando método imunológico e quimioterapêutico para o tratamento de câncer BR112021017375A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962812703P 2019-03-01 2019-03-01
PCT/US2020/020395 WO2020180686A1 (en) 2019-03-01 2020-02-28 Pharmaceutical composition combining immunologic and chemotherapeutic method for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112021017375A2 true BR112021017375A2 (pt) 2021-11-16

Family

ID=70190083

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017375A BR112021017375A2 (pt) 2019-03-01 2020-02-28 Composição farmacêutica combinando método imunológico e quimioterapêutico para o tratamento de câncer

Country Status (10)

Country Link
US (1) US20200277379A1 (pt)
EP (1) EP3931221A1 (pt)
JP (1) JP2022524979A (pt)
KR (1) KR20210136058A (pt)
AU (1) AU2020232595A1 (pt)
BR (1) BR112021017375A2 (pt)
CA (1) CA3131132A1 (pt)
IL (1) IL285917A (pt)
WO (1) WO2020180686A1 (pt)
ZA (1) ZA202106204B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016007411A (es) 2013-12-05 2017-01-09 Rfemb Holdings Llc Presentacion de antigeno de cancer mejorado a celulas que presentan por la descomposicion electrica de membrana por radiofrecuencia (rf-rmb) como un mecanismo adyuvante para la inmunoterapia.
CA2975123A1 (en) 2015-01-30 2016-08-04 Rfemb Holdings, Llc Radio frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue
CA3011460A1 (en) 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer
CN112516319A (zh) * 2020-12-08 2021-03-19 华中农业大学 用于治疗乳腺癌的组合药剂
CN115678850A (zh) * 2021-07-30 2023-02-03 苏州博思得电气有限公司 一种促进肿瘤细胞凋亡的方法
CN114306614B (zh) * 2021-12-06 2024-02-06 上海市第十人民医院 一种生物响应性免疫凝胶及其制备方法与应用
WO2023141560A2 (en) * 2022-01-20 2023-07-27 Synthetic Biologics, Inc. Alkaline phosphatase for use in oncology
CN115845254B (zh) * 2022-11-23 2024-02-02 湖南安泰康成生物科技有限公司 小细胞肺癌治疗系统以及交变电场发生装置

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4785806A (en) 1987-01-08 1988-11-22 Yale University Laser ablation process and apparatus
US4945912A (en) 1988-11-25 1990-08-07 Sensor Electronics, Inc. Catheter with radiofrequency heating applicator
US5383917A (en) 1991-07-05 1995-01-24 Jawahar M. Desai Device and method for multi-phase radio-frequency ablation
US20040002647A1 (en) 1991-10-18 2004-01-01 Ashvin Desai Gel injection treatment of body parts
CA2122834C (en) 1991-11-04 1999-10-05 Henry Nita Ultrasonic ablation device adapted for guidewire passage
US5524620A (en) 1991-11-12 1996-06-11 November Technologies Ltd. Ablation of blood thrombi by means of acoustic energy
US5231047A (en) 1991-12-19 1993-07-27 Energy Conversion Devices, Inc. High quality photovoltaic semiconductor material and laser ablation method of fabrication same
US5540681A (en) 1992-04-10 1996-07-30 Medtronic Cardiorhythm Method and system for radiofrequency ablation of tissue
US5573533A (en) 1992-04-10 1996-11-12 Medtronic Cardiorhythm Method and system for radiofrequency ablation of cardiac tissue
US5487740A (en) 1994-03-02 1996-01-30 Energy Life Systems Corporation Laser device for ablation of human tissue
US6813520B2 (en) 1996-04-12 2004-11-02 Novacept Method for ablating and/or coagulating tissue using moisture transport
US5800487A (en) 1996-07-23 1998-09-01 Endocare, Inc. Cryoprobe
US7220257B1 (en) 2000-07-25 2007-05-22 Scimed Life Systems, Inc. Cryotreatment device and method
US6132424A (en) 1998-03-13 2000-10-17 Lasersight Technologies Inc. Smooth and uniform laser ablation apparatus and method
US7001378B2 (en) 1998-03-31 2006-02-21 Innercool Therapies, Inc. Method and device for performing cooling or cryo-therapies, for, e.g., angioplasty with reduced restenosis or pulmonary vein cell necrosis to inhibit atrial fibrillation employing tissue protection
FR2778573B1 (fr) 1998-05-13 2000-09-22 Technomed Medical Systems Reglage de frequence dans un appareil de traitement par ultrasons focalises de haute intensite
US20050255039A1 (en) 1998-06-26 2005-11-17 Pro Surg, Inc., A California Corporation Gel injection treatment of breast, fibroids & endometrial ablation
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6325796B1 (en) 1999-05-04 2001-12-04 Afx, Inc. Microwave ablation instrument with insertion probe
US7226446B1 (en) 1999-05-04 2007-06-05 Dinesh Mody Surgical microwave ablation assembly
US6306132B1 (en) 1999-06-17 2001-10-23 Vivant Medical Modular biopsy and microwave ablation needle delivery apparatus adapted to in situ assembly and method of use
US7033352B1 (en) 2000-01-18 2006-04-25 Afx, Inc. Flexible ablation instrument
US6595934B1 (en) 2000-01-19 2003-07-22 Medtronic Xomed, Inc. Methods of skin rejuvenation using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions
US7706882B2 (en) 2000-01-19 2010-04-27 Medtronic, Inc. Methods of using high intensity focused ultrasound to form an ablated tissue area
US6471696B1 (en) 2000-04-12 2002-10-29 Afx, Inc. Microwave ablation instrument with a directional radiation pattern
US6932814B2 (en) 2000-07-10 2005-08-23 The United States Of America As Represented By The Department Of Health And Human Services Radiofrequency probes for tissue treatment and methods of use
US6811562B1 (en) 2000-07-31 2004-11-02 Epicor, Inc. Procedures for photodynamic cardiac ablation therapy and devices for those procedures
US6821274B2 (en) 2001-03-07 2004-11-23 Gendel Ltd. Ultrasound therapy for selective cell ablation
US6648880B2 (en) 2001-02-16 2003-11-18 Cryocath Technologies Inc. Method of using cryotreatment to treat brain tissue
AU2002326952A1 (en) 2001-09-19 2003-04-01 Urologix, Inc. Microwave ablation device
EP1429820A4 (en) 2001-09-27 2007-11-14 Galil Medical Ltd APPARATUS AND METHOD FOR CRYOGENIC ANGIOPLASTY
US6579287B2 (en) 2001-10-09 2003-06-17 Cryocath Technologies Inc. Cryosurgical ablation device having sequential injection and method therefor
US8974446B2 (en) 2001-10-11 2015-03-10 St. Jude Medical, Inc. Ultrasound ablation apparatus with discrete staggered ablation zones
EP1558326A4 (en) 2002-10-17 2007-08-15 Pro Surg Inc GELINJECTION DEVICE AND TREATMENT OF THE CHEST, FIBROID AND ANDOMETRIUM ABLATION
US7410484B2 (en) * 2003-01-15 2008-08-12 Cryodynamics, Llc Cryotherapy probe
ES2597377T3 (es) 2003-04-03 2017-01-18 Galil Medical Ltd Aparato para crioablación delimitada con precisión
US7311701B2 (en) 2003-06-10 2007-12-25 Cierra, Inc. Methods and apparatus for non-invasively treating atrial fibrillation using high intensity focused ultrasound
US7670335B2 (en) 2003-07-21 2010-03-02 Biosense Webster, Inc. Ablation device with spiral array ultrasound transducer
ES2729378T3 (es) 2003-12-24 2019-11-04 Univ California Ablación de tejido con electroporación irreversible
US20060052706A1 (en) 2004-08-20 2006-03-09 Kullervo Hynynen Phased array ultrasound for cardiac ablation
US20060056480A1 (en) 2004-09-15 2006-03-16 Mielke Michael M Actively stabilized systems for the generation of ultrashort optical pulses
WO2006095330A2 (en) 2005-03-10 2006-09-14 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
US20070129712A1 (en) 2005-12-01 2007-06-07 Ceramoptec Industries, Inc. Benign prostate hyperplasia treatment using photosensitizer and laser ablation
ES2551306T3 (es) 2006-02-13 2015-11-17 Oncolytics Biotech Inc. Uso de inmunosupresión local de baja dosis para potenciar una terapia viral oncolítica
US20080039746A1 (en) 2006-05-25 2008-02-14 Medtronic, Inc. Methods of using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions
US20090000184A1 (en) 2006-07-21 2009-01-01 Garwood Anthony J Method of processing bio-mass matter into renewable fluid fuels (synthetic diesel)
WO2008021321A2 (en) 2006-08-17 2008-02-21 Rjf Holdings Iv, Inc Method and apparatus for plasma incision of cardiovascular tissue
JP5198466B2 (ja) 2006-12-06 2013-05-15 ボストン サイエンティフィック リミテッド パルス変調された無線周波数エネルギーを用いる組織焼灼エネルギー発生器
WO2008140621A2 (en) 2006-12-21 2008-11-20 Mount Sinai School Of Medicine Of New York University Transgenic oncolytic viruses and uses thereof
US7655004B2 (en) 2007-02-15 2010-02-02 Ethicon Endo-Surgery, Inc. Electroporation ablation apparatus, system, and method
CA2679405C (en) 2007-02-27 2015-12-22 Erik N. K. Cressman Thermochemical ablation of bodily tissue
JP2010519955A (ja) 2007-03-01 2010-06-10 ナノスペクトラ、バイオサイアンセズ、インク 循環する細胞の体外アブレーションのためのデバイスおよび方法
WO2008142686A2 (en) 2007-05-21 2008-11-27 Uc-Care Ltd. Ablation probe
JP4635233B2 (ja) 2007-09-06 2011-02-23 株式会社ハイレックスコーポレーション 衝撃波アブレーションシステム
US20090192505A1 (en) 2007-12-05 2009-07-30 Reset Medical, Inc. Method for cryospray ablation
US7996078B2 (en) 2007-12-31 2011-08-09 St. Jude Medical, Atrial Fibrillation Division, Inc. Systems and methods of photodynamic-based cardiac ablation via the esophagus
US9867652B2 (en) 2008-04-29 2018-01-16 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
US8221411B2 (en) 2008-07-28 2012-07-17 Medtronic, Inc. Systems and methods for cardiac tissue electroporation ablation
WO2010118387A1 (en) 2009-04-09 2010-10-14 Virginia Tech Intellectual Properties, Inc. Integration of very short electric pulses for minimally to noninvasive electroporation
WO2011006017A1 (en) 2009-07-08 2011-01-13 Sanuwave, Inc. Usage of extracorporeal and intracorporeal pressure shock waves in medicine
EP2503950B1 (en) 2009-11-24 2015-04-29 Regents of the University of Minnesota Systems for chemical ablation
US8690866B2 (en) 2010-08-23 2014-04-08 Covidien Lp Ablation devices utilizing exothermic chemical reactions, system including same, and methods of ablating tissue using same
JP2014501574A (ja) 2010-11-23 2014-01-23 ヴァージニア テック インテレクチュアル プロパティーズ，インコーポレーテッド 異常な細胞集団を治療するか、組織スキャフォールドを生成するために組織の脈管構造を用いる不可逆的電気穿孔
WO2012088149A2 (en) 2010-12-20 2012-06-28 Virginia Tech Intellectual Properties, Inc. High-frequency electroporation for cancer therapy
WO2012158553A2 (en) 2011-05-13 2012-11-22 Broncus Technologies, Inc. Methods and devices for excision of tissue
US9204918B2 (en) 2011-09-28 2015-12-08 RELIGN Corporation Medical ablation system and method of use
CN107080561B (zh) 2011-12-09 2020-09-11 麦特文申公司 用于神经调节的设备、系统和方法
US20150272666A1 (en) 2012-11-02 2015-10-01 Lixiao Wang Chemical Ablation Formulations and Methods of Treatments for Various Diseases
US10537375B2 (en) 2015-04-24 2020-01-21 Neurotronic, Inc. Chemical ablation and method of treatment for various diseases
US10154869B2 (en) 2013-08-02 2018-12-18 Gary M. Onik System and method for creating radio-frequency energy electrical membrane breakdown for tissue ablation
CN104415335A (zh) * 2013-09-02 2015-03-18 北京中康万达医药科技有限公司 体内个体化系统免疫治疗方法和装置
MX2016007411A (es) 2013-12-05 2017-01-09 Rfemb Holdings Llc Presentacion de antigeno de cancer mejorado a celulas que presentan por la descomposicion electrica de membrana por radiofrecuencia (rf-rmb) como un mecanismo adyuvante para la inmunoterapia.
US10023858B2 (en) 2014-05-29 2018-07-17 U.S. Patent Innovations, LLC System and method for selective ablation of cancer cells with cold atmospheric plasma
US10376674B2 (en) 2014-09-15 2019-08-13 Ethicon, Inc. System and method for targeted delivery of therapeutic agents to tissue
CA2975123A1 (en) 2015-01-30 2016-08-04 Rfemb Holdings, Llc Radio frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue
WO2016126811A1 (en) 2015-02-04 2016-08-11 Rfemb Holdings, Llc Radio-frequency electrical membrane breakdown for the treatment of adipose tissue and removal of unwanted body fat
WO2016126905A2 (en) 2015-02-04 2016-08-11 Rfemb Holdings, Llc Radio-frequency electrical membrane breakdown for reducing restenosis
US20180028267A1 (en) 2015-02-04 2018-02-01 Rfemb Holdings, Llc Radio-frequency electrical membrane breakdown for the treatment of benign prostatic hyperplasia
CA2975888A1 (en) 2015-02-06 2016-08-11 Rfemb Holdings, Llc Radio-frequency electrical membrane breakdown for the treatment of cardiac rhythm disorders and for renal neuromodulation
AU2016220549B2 (en) 2015-02-17 2021-09-23 Nanyang Technological University Regenerable draw solute for osmotically driven processes
CA3011460A1 (en) 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer

Also Published As

Publication number Publication date
JP2022524979A (ja) 2022-05-11
EP3931221A1 (en) 2022-01-05
CA3131132A1 (en) 2020-09-10
ZA202106204B (en) 2022-04-28
AU2020232595A1 (en) 2021-09-16
KR20210136058A (ko) 2021-11-16
WO2020180686A1 (en) 2020-09-10
IL285917A (en) 2021-10-31
US20200277379A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
BR112021017375A2 (pt) Composição farmacêutica combinando método imunológico e quimioterapêutico para o tratamento de câncer
BR112022008535A2 (pt) Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras
BR112022008534A2 (pt) Compostos, composição farmacêutica, conjugado e métodos para tratar câncer e para tratar um distúrbio relacionado à proteína ras
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
MX2022010270A (es) Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion.
CY1122038T1 (el) Ετεροδιλειτουργικοι αναστολεις των ε-σελεκτινων και των υποδοχεων χημειοκινης cxcr4
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
MX2017016492A (es) Metodos para tratar tumores solidos usando terapia de combinacion de nanoparticula del inhibidor del objetivo mamifero de la rapamicina (mtor).
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
BR112015030377A2 (pt) preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação
BR112023022819A2 (pt) Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
BR112019023909A2 (pt) método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio.
BR112022007158A2 (pt) Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
BR112017022653A2 (pt) ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph?
CO2019003865A2 (es) Proteína terapéutica
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
BR112016023011A2 (pt) tratamento de câncer gástrico
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
PH12018501769A1 (en) Medicament for treatment of diabetic foot infections
BR112023016320A2 (pt) Composição terapêutica e método de combinação de imunoterapia multiplex com vacina contra câncer para tratamento de câncer
BR112021016923A2 (pt) Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
EA202192695A1 (ru) Комбинации ингибиторов транскрипции и ингибиторов иммунных контрольных точек для лечения заболевания

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2732 DE 16-05-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.